Home/Pipeline/MRD / Recurrence Monitoring Test

MRD / Recurrence Monitoring Test

Primary and Metastatic CNS Malignancies

Development/ValidationActive

Key Facts

Indication
Primary and Metastatic CNS Malignancies
Phase
Development/Validation
Status
Active
Company

About Belay Diagnostics

Belay Diagnostics is a private, pre-revenue diagnostics company pioneering CSF liquid biopsy for CNS cancers. The company has developed three proprietary tests designed to detect and genomically profile tumors from cerebrospinal fluid, addressing the significant limitations of current standards like MRI, cytology, and invasive surgical biopsies. Founded by a team of neurosurgeons, scientists, and entrepreneurs with deep expertise in neuro-oncology and diagnostics, Belay is positioned to tap into a substantial unmet need in neuro-oncology. Its success hinges on clinical validation, market adoption, and navigating the complex reimbursement landscape for novel diagnostic tests.

View full company profile

Therapeutic Areas

Other Primary and Metastatic CNS Malignancies Drugs

DrugCompanyPhase
Diagnostic & Molecular Profiling TestBelay DiagnosticsDevelopment/Validation
Therapy Selection & Monitoring TestBelay DiagnosticsDevelopment/Validation